clindoxyl once daily gel
glaxosmithkline pte ltd - benzoyl peroxide hydrous; clindamycin phosphate - gel - 6.67% w/w - benzoyl peroxide hydrous 6.67% w/w; clindamycin phosphate 1.28% w/w
warticon 0.15 %w/w cream
glaxosmithkline (ireland) limited - podophyllotoxin - cream - 0.15 %w/w - antivirals
duac once daily 10 + 30 mg/g gel
glaxosmithkline (ireland) limited - benzoyl peroxide hydrous, clindamycin phosphate - gel - 10 + 30 mg/g - antiinfectives for treatment of acne
spectraban ultra 28 (sunscreen)
stiefel -
isotrexin 20 mg/g + 0.5 mg/g gel
glaxosmithkline (ireland) limited - isotretinoin; erythromycin - gel - 20+0.5 milligram(s)/gram - isotretinoin, combinations
stieprox 15 mg/g shampoo
glaxosmithkline (ireland) limited - ciclopirox olamine - shampoo - 15 milligram(s)/gram - other antifungals for topical use; ciclopirox
isotrex 0.5 mg/g gel
glaxosmithkline (ireland) limited - isotretinoin - gel - 0.5 milligram(s)/gram - retinoids for topical use in acne; isotretinoin
duofilm cutaneous solutionsalicylic acid 16.7% w/wlactic acid 15.0% w/w
glaxosmithkline consumer healthcare (ireland) limited - salicylic acid; lactic acid - cutaneous solution - 16.7 %w/w + 15.0 percent weight/weight - wart and anti-corn preparations
oilatum junior flare-up bath additivelight liquid paraffin 52.5%w/wbenzalkonium chloride 6.0%w/wtriclosan <p styl
glaxosmithkline consumer healthcare (ireland) limited - benzalkonium chloride; light liquid paraffin; triclosan - bath additive - 52.5%w/w +6.0%w/w +2.0 percent weight/weight - soft paraffin and fat products
soriatane- acitretin capsule
stiefel laboratories inc - acitretin (unii: lch760e9t7) (acitretin - unii:lch760e9t7) - acitretin 10 mg - soriatane is indicated for the treatment of severe psoriasis in adults. because of significant adverse effects associated with its use, soriatane should be prescribed only by those knowledgeable in the systemic use of retinoids. in females of reproductive potential, soriatane should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed contraindications and warnings — soriatane can cause severe birth defects). most patients experience relapse of psoriasis after discontinuing therapy. subsequent courses, when clinically indicated, have produced efficacy results similar to the initial course of therapy. see boxed contraindications and warnings. soriatane is contraindicated in patients with severely impaired liver or kidney function and in patients with chronic abnormally elevated blood lipid values (see boxed warnings:hepatotoxicity, warnings:lipids and possible cardiovascular effects, and precautions). an